Find policies, billing codes, payers, states, and providers
CPT 0041U: Lyme ImmunoBlot IgM (IGeneX)
CPT code 0041U designates the proprietary Lyme ImmunoBlot IgM assay produced by IGeneX Inc., a laboratory serology test that detects IgM antibodies to five recombinant protein groups for identification of Borrelia burgdorferi, the causative agent of Lyme disease. As a PLA code, 0041U is unique to a single manufacturer and lab and is used where clinicians and payers need a specific identifier for this proprietary assay. Nationally, PLA codes like 0041U matter because they enable tracking, billing, and policy decisions for tests that do not have generic CPT equivalents.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the clinical context for the assay, expected sites of service (clinical laboratories and independent diagnostic testing facilities), and which payers are addressed. The publication outlines benchmarks and payment considerations where available, clarifies coding and billing implications of using a PLA code, and situates the assay within laboratory diagnostic workflows for suspected Lyme disease. Data not available in the input is identified where applicable.
Customize your policy alerts
Sign up for cpt 0041U policy alerts
Get alerted when payer policies referencing 0041U are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 0041U is a Proprietary Laboratory Analyses (PLA) code describing the Lyme ImmunoBlot IgM test from IGeneX Inc. The test detects IgM antibodies to five recombinant protein groups to identify Borrelia burgdorferi, the tick-borne bacterium that causes Lyme disease.
Service type: Laboratory / Infectious disease serology
Typical site of service: Clinical laboratory or independent diagnostic testing facility (IDTF)